Díaz-Casañas E, Rodríguez-Moya VS, Montes de Oca MN

Language: Spanish
References: 18
Page: 1-5
PDF size: 690.24 Kb.

Text Extraction

No abstract.

REFERENCES

1. Word Health Organization. Situation reports provide the latest updates on the COVID-19 outbreak [Internet]. Ginebra : Word Health Organization; 2020 [Citado 04/05/2020]. Disponible en: Disponible en: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/

2. Judy Y. Coronavirus - A Primer. Asia-Pacific Biotech News. Asia Pacific Biotech News [Internet]. 2020 [Citado 12/03/2020];24:[aprox. 2 p.]. Disponible en: Disponible en: http://www.worldscientific.com

3. Wu Z, Mc Googan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA [Internet]. 2020 [Citado 20/04/2020];323(13):1239-42. Disponible en: Disponible en: http://jamanetwork.com/journals/jama/fullarticle/2762130

4. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med [Internet]. 2020 [Citado 20/04/2020];382:[aprox. 2 p.]. Disponible en: Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092819/pdf/NEJMoa2002032.pdf

5. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med [Internet]. 2020. [Citado 12/03/2020];8:[aprox. 2 p.]. Disponible en: Disponible en: http://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30079-5/fulltext

6. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA [Internet]. 2020 [Citado 27/04/2020];323:[aprox. 2 p.]. Disponible en: Disponible en: http://www.udd.cl/wp-content/uploads/2020/03/descripcion-sintomas-pronostico-en-138-pacientes-jama_wang_2020_oi_200019.pdf

7. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet [Internet]. 2020 [Citado 15/04/2020];395:[aprox. 2 p.]. Disponible en: Disponible en: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30566-3/fulltext

8. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy [Internet]. 2020 [Citado 15/04/2020];75:[aprox. 2 p.]. Disponible en: Disponible en: https://onlinelibrary.wiley.com/doi/full/10.1111/all.14238

9. Hoffmann M, Kleine Weber H, Schroeder S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell [Internet]. 2020 [Citado 27/04/2020];181:271-80. Disponible en: Disponible en: http://www.cell.com/cell/abstract/S0092-8674(20)30229-4

10. Carsana L, Sonzogni A, Nasr A, Rossi R, Pellegrinelli A, Zerbi P, et al. Pulmonary post-mortem findings in a large series of COVID-19 cases from Northern Italy En: Latest BMJ blogs [Internet]. London: Latest BMJ blogs;2020 [Citado 27/04/2020]. Disponible en: Disponible en: http://doi.org/10.1101/2020.04.19.20054262

11. Alhazzani W, Møller MH, Arabi YM, Loeb M, Ng Gong M, Fan E, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med [Internet].2020 [Citado 20/03/2020];46:[aprox. 2 p.]. Disponible en: Disponible en: http://doi.org/10.1007/s00134-020-06022-5

12. Centro Nacional de Sanidad Agropecuaria. Surfactante pulmonar natural de origen porcino. Patente de la República de Cuba CU 22479 A1. 1997. Disponible en: http://www.censa.edu.cu/index.php/2015/12/09/english-surfacen/

13. Blanco Hidalgo O, Beltrán Núñez A, González Rodríguez D, Sánchez Calero J, Fernández Limia O, Faure García R, et al. Some Anti- Inflammatory Properties of a Natural Pulmonary Surfactan: SURFACEN®. 2000. Applied Cardiopulmonary Pathophysiology [Internet]. 2000 [Citado 20/04/2020];9(3):201-2. Disponible en: Disponible en: https://www.researchgate.net/publication/236150079_Some_anti-inflammatory_properties_of_a_natural_pulmonary_surfactant_Surfacen

14. Blanco Hidalgo O, Riverón Alemán Y, De Armas Sanabria E, Sánchez Calero J, Faure García R, Fernández Limia O. SURFACEN® inhibe el crecimiento de bacterias causantes de infecciones respiratorias. Biotecnología Aplicada [Internet]. 2005 [Citado 27/04/2020];22:279-81. Disponible en: Disponible en: https://elfosscientiae.cigb.edu.cu/PDFs/Biotecnol%20Apl/2005/22/4/BA002204OC279-281.pdf

15. Blanco O, Lugones Y, Díaz E, Monzote L. In vitro activity of the clinical pulmonary surfactant Surfacen® against Leishmania amazonensis. Rev Inst Med Trop [Internet]. 2011 [Citado 28/04/2020];53(4):235-8. Disponible en: Disponible en: https://www.scielo.br/scielo.php?script=sci_arttext&pid=S0036-46652011000400012&lng=en

16. Blanco Hidalgo O, Cruz Rodríguez A, Ospina Ramírez OL, López Rodríguez E, Vázquez Martínez L, Pérez Gil J. Interfacial behavior and structural properties of a clinical lung surfactant from porcine source. Biochim Biophys Acta [Internet]. 2012 [Citado 28/04/2020];1818(11):2756-66. Disponible en: Disponible en: https://www.sciencedirect.com/science/article/pii/S0005273612002210

17. Díaz Casañas E, Morilla Guzmán AA, Rodríguez Moya VS, Hidalgo Sánchez AO, Barrese Pérez Y. Estrategia de desarrollo clínico para la evaluación de la eficacia y seguridad de SURFACEN. Rev Arch Méd Camagüey [Internet]. 2019 [Citado 20/04/2020];23(4):[aprox. 2 p.]. Disponible en: Disponible en: https://www.revistaamc.sld.cu/index.php/amc/article/view/6440

18. Ministerio de salud Pública. Protocolo Nacional MINSAP vs COVID-19 [Internet]. La Habana: Ministerio de Salud Pública; 2020 [Citado 04/05/2020]. Disponible en: Disponible en: http://instituciones.sld.cu/facultadfinlayalbarran/files/2020/04/Protocolo-Cuba-vs-COVID-4-4-2020.pdf